A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors

Những quyển sách tương tự

• FDA and EMA Biosimilar Approvals
  Bằng: Jung, Emily H., et al.
  Được phát hành: (2019)
• The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
  Bằng: Gherghescu, Ioana, et al.
  Được phát hành: (2020)
• Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
  Bằng: Hatswell, Anthony J, et al.
  Được phát hành: (2016)
• FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
  Bằng: Solassol, Isabelle, et al.
  Được phát hành: (2019)
• Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
  Bằng: Hennrich, Ute, et al.
  Được phát hành: (2019)